Italian pharma push, biosimilars & insurance growth

Timeline

1. 2 days ago

   [HEALTH] 8 sources

   Italy drug spending reaches €39.3 bn in 2025, antidiabetic use soars

   Italy’s 2025 pharmaceutical spend rose 6% to €39.3 bn, with public funds at €28.4 bn and out‑of‑pocket at €10.7 bn; antidiabetic drug spending jumped 35% to €1.59 bn, driven by semaglutide and tirzepatide.

2. 19 days ago

   [HEALTH] 45 sources

   AIFA's drug pricing overhaul faces industry and political criticism in Italy

   AIFA plans to revamp Italy's drug reimbursement list, limiting payments to the cheapest active ingredient within broader therapeutic groups. Politicians and pharma groups warn the move could shift costs to the

3. 22 days ago

   [BUSINESS] 6 sources

   Italian generic drug association cites €7.4 bn state savings and calls for payback reform

   Egualia reports €7.4 bn saved by generics and biosimilars, 11 k jobs, and calls for pay‑back reform to protect margins and boost domestic drug production in Italy.

4. 25 days ago

   [HEALTH] 5 sources

   Italian drug regulator AIFA adds detailed market status to 'Cerca un Farmaco' service

   AIFA’s ‘Cerca un farmaco’ portal now shows per‑pack commercialisation status—available, unavailable, scarce or never marketed—and adds shortage reasons, timelines and guidance for pharmacists.

5. 25 days ago

   [HEALTH] 5 sources

   Italian officials seek to curb Teva drug use in public pharmacies

   Italian officials in Fano and the national parliament are urging limits on Teva drugs in public pharmacies and calling for a balanced drug formulary that protects innovative treatments while controlling costs.

6. 28 days ago

   [BUSINESS] 2 sources

   Italian insurance market grows while trust between firms erodes

   Italy’s insurance credit and surety market is expanding—global forecast $31.85 bn by 2031 and domestic premiums up 9.2%—but a trust crisis is straining SME access to guarantees, prompting calls for cultural re‑

7. about 1 month ago

   [HEALTH] 7 sources

   Italy hosts forum on life‑science competitiveness and drug access

   A Rome forum gathered government, academia and pharma to discuss Italy’s life‑science competitiveness, MFN drug pricing and ways to speed patient access, citing a widening EU‑US research gap.

8. about 1 month ago

   [BUSINESS] 2 sources

   Italian pharmaceutical sector sees modest retail growth but strong export surge

   Italy’s pharma market grew modestly in retail while exports surged 28.5% in 2025, highlighting strong OTC sales, dominant brick‑and‑mortar pharmacies and a rising need for specialised workforce skills.

9. about 1 month ago

   [HEALTH] 4 sources

   Italy's private health insurance market expands as citizens turn to self‑care

   Italy's health insurance market surged to €4.9 bn in 2025, with 40% of Italians now covered, as long public wait times drive self‑medication and demand for hybrid pharmacy services across Europe.

10. about 1 month ago

    [HEALTH] 2 sources

    Italy's pharmacy sector examines supplemental health insurance differences

    Italy's pharmacy sector compares two supplemental health insurance schemes, Fasifar and Emapi, while broader industry discussions cover legislation, biosimilars, AI in drug development, and medical device采购.

11. about 1 month ago

    [HEALTH] 3 sources

    Simona Autunnali says Italy's drug formulary update must not mask cost‑saving motives

    Snami chief Simona Autunnali urges Italy's drug formulary revision to prioritize clinical appropriateness over cost cuts, while a new pharmacist guide promotes evidence‑based care for minor ailments.

12. about 1 month ago

    [HEALTH] 11 sources

    Italian authorities reject reimbursement for new Alzheimer drugs while emphasizing biosimilar cost savings

    Italy’s drug agency rejects reimbursement for new Alzheimer antibodies over modest benefit, while Sandoz stresses biosimilars’ €56 bn EU savings and calls for strong governance.

13. about 2 months ago

    [HEALTH] 4 sources

    Italy's drug policy wrestles with rising costs and biosimilar sustainability

    Italy's biosimilar success faces procurement concentration, while lawmakers decry rising drug costs and plans to shift reimbursements onto citizens.

14. about 2 months ago

    [BUSINESS] 18 sources

    Farmindustria emphasises pharma as a strategic asset for Italy and Europe

    Farmindustria re‑elected Marcello Cattani, warns pharma spending is an investment; round‑table in Rome flags drug supply chains as strategic for Italy’s security and European autonomy, urging regulatory support

15. about 2 months ago

    [HEALTH] 2 sources

    Italy's pharmaceutical spending reforms risk up to €1 billion extra cost

    Italy aims to curb soaring drug costs by expanding generic equivalents and a new reference‑price system, but a €4.7 bn budget overshoot and a potential €1 bn patient burden raise concerns.

16. about 2 months ago

    [HEALTH] 3 sources

    AIFA and FOFI sign pact to boost AI‑driven digital tools for Italian pharmacists

    AIFA and FOFI have signed a three‑year pact to share drug data via Italy’s Pdnd platform and launch an AI service for pharmacists, aiming to improve chronic‑care monitoring and tackle medication shortages.

17. about 2 months ago

    [HEALTH] 3 sources

    Italy's Health Ministry flags forensic medicine roadmap and pharma traceability lag

    Italy’s Health Ministry launches a forensic‑medicine strategic plan while a Gimbe report warns the country lags in EU‑required digital drug traceability, risking public‑health safety.

18. about 2 months ago

    [HEALTH] 2 sources

    Italy accelerates drug discovery with AI and funds rare‑disease research

    AI is speeding Italian drug development while AIFA awards €17.5 million to 19 rare‑disease research projects, aiming to cut costs and expand treatment options.

19. about 2 months ago

    [BUSINESS] 2 sources

    Bayer Italy CEO Arianna Gregis details AI‑driven innovation and export push

    Bayer Italy CEO Arianna Gregis says the firm’s strategy hinges on innovation, AI‑driven drug development and strategic alliances, with its Garbagnate Milanese plant producing 8 bn tablets a year for export and,

20. about 2 months ago

    [HEALTH] 2 sources

    Italian health sector boosts innovation with clinical engineering focus and upgraded pharmacy labs

    Italy advances health innovation: clinical engineers link new tech to care, and Reggio Emilia’s pharmacy labs are upgraded for advanced, safe therapies.

21. about 2 months ago

    [BUSINESS] 4 sources

    Italy's pharma sector calls for digital, AI and skill reforms to boost competitiveness

    Italy’s pharma industry urges digital, AI and regulatory reforms, plus focused skill training, to maintain EU leadership and attract global R&D investment.

22. 2 months ago

    [BUSINESS] 2 sources

    Lazio biotech sector fuels regional economic growth and competitiveness

    Lazio’s biotech and pharma cluster, backed by universities and firms like Bayer Italia, is driving regional growth, high‑skill jobs and export strength while seeking faster regulation and more R&D investment.

23. 2 months ago

    [HEALTH] 4 sources

    Italian scientists say AI can cut drug‑development costs by 25% and timelines by 40%

    Italian experts say AI can cut drug‑development costs by 25% and reduce timelines by 40%, urging faster tech transfer and a public‑private hub to boost Italy’s pharma competitiveness.

24. 2 months ago

    [BUSINESS] 3 sources

    Italian Pharma Leaders Discuss Skills and AI at June 9 Adnkronos Talk

    Italian pharma leaders will discuss AI, big data, talent and training at a live Adnkronos talk on 9 June, seeking a skills roadmap for the sector.

25. 3 months ago

    [BUSINESS] 23 sources

    Italy positions pharmaceutical industry as growth engine while stressing patient‑centred innovation

    Italy’s pharma sector is hailed as an economic driver, with record export growth and €4.5 bn R&D spending, while experts stress patient‑centred access and faster EU regulations.